Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial

EAST HANOVER, N.J., June 1, 2019 /PRNewswire/ -- Novartis today announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy1. The Phase 3 MONALEESA-7 trial evaluated Kisqali plus endocrine therapy (goserelin plus either an aromatase...

from PR Newswire: https://prn.to/2JTkhGL